AR070346A1 - Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos - Google Patents
Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicosInfo
- Publication number
- AR070346A1 AR070346A1 ARP090100415A ARP090100415A AR070346A1 AR 070346 A1 AR070346 A1 AR 070346A1 AR P090100415 A ARP090100415 A AR P090100415A AR P090100415 A ARP090100415 A AR P090100415A AR 070346 A1 AR070346 A1 AR 070346A1
- Authority
- AR
- Argentina
- Prior art keywords
- tslpr
- inflammatory
- lymphopyetine
- timica
- stromal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Reivindicacion 1: Un compuesto de union que se une específicamente al TSLPR de humano y de cyno, que comprende: al menos una region variable de cadena pesada de anticuerpo, o un fragmento de union al TSLPR del mismo, comprendiendo dicha region variable de cadena pesada al menos una secuencia de la CDR seleccionada del grupo integrado por los NOs ID SEC: 1, 2, 3, 73, 7, 8, 9, 13, 14, 15, 19, 20, 21, 25, 26, 27, 31, 32, 33, 37, 38, 39, 43, 44 y 45, o una variante de cualquiera de dichas secuencias; o al menos una region variable de cadena liviana de anticuerpo, o un fragmento de union al TSLPR del mismo, comprendiendo dicha region variable de cadena liviana al menos una secuencia de la CDR seleccionada del grupo integrado por los NOs ID SEC: 4, 5, 6, 74, 10, 11, 12, 16, 17, 18, 22, 23, 24, 28, 29, 30, 34, 35, 36, 40, 41, 42, 46, 47 y 48, o una variante de cualquiera de dichas secuencias.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2683308P | 2008-02-07 | 2008-02-07 | |
US4203008P | 2008-04-03 | 2008-04-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR070346A1 true AR070346A1 (es) | 2010-03-31 |
Family
ID=40622088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090100415A AR070346A1 (es) | 2008-02-07 | 2009-02-06 | Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos |
Country Status (8)
Country | Link |
---|---|
US (1) | US8475793B2 (es) |
EP (1) | EP2250199B1 (es) |
JP (2) | JP2011511638A (es) |
CN (1) | CN101986784A (es) |
AR (1) | AR070346A1 (es) |
CA (1) | CA2713935C (es) |
MX (1) | MX2010008688A (es) |
WO (1) | WO2009100324A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100034015A (ko) | 2007-06-20 | 2010-03-31 | 아이알엠 엘엘씨 | 알레르기 질환 치료를 위한 방법 및 조성물 |
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
MX2010013020A (es) * | 2008-05-27 | 2011-03-21 | Intra Cellular Therapies Inc | Metodos y composiciones para trastornos del sueño y otros trastornos. |
AR082163A1 (es) | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos |
WO2012054438A1 (en) * | 2010-10-22 | 2012-04-26 | Schering Corporation | Anti-pcsk9 |
MY177098A (en) * | 2013-08-09 | 2020-09-05 | Astellas Pharma Inc | Novel anti-human tslp receptor antibody |
US9790506B2 (en) | 2013-10-02 | 2017-10-17 | The Regents Of The University Of California | Diagnostic and screening methods for atopic dermatitis |
MX2016007219A (es) | 2013-12-03 | 2016-09-16 | Intra-Cellular Therapies Inc | Metodos novedosos. |
RU2701346C1 (ru) * | 2013-12-06 | 2019-09-25 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения |
US10000561B2 (en) | 2015-09-09 | 2018-06-19 | Novartis Ag | Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules |
LT3347377T (lt) | 2015-09-09 | 2021-05-25 | Novartis Ag | Užkrūčio liaukos stromos limfopoetiną (tslp) rišantys antikūnai ir antikūnų panaudojimo būdai |
SG11201805123XA (en) | 2015-12-18 | 2018-07-30 | Astellas Pharma Inc | Pharmaceutical composition comprising anti-human tslp receptor antibody |
CN113786407A (zh) | 2016-01-26 | 2021-12-14 | 细胞内治疗公司 | 有机化合物 |
WO2017146011A1 (ja) * | 2016-02-22 | 2017-08-31 | 国立大学法人 千葉大学 | アレルギー性鼻炎の診断用バイオマーカー |
US11014925B2 (en) | 2016-03-28 | 2021-05-25 | Intra-Cellular Therapies, Inc. | Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide |
JP7013454B2 (ja) | 2016-10-12 | 2022-02-15 | イントラ-セルラー・セラピーズ・インコーポレイテッド | アモルファス固体分散体 |
JP6987868B2 (ja) | 2016-12-29 | 2022-01-05 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
MX2021013640A (es) | 2017-03-24 | 2022-08-31 | Intra Cellular Therapies Inc | Composiciones novedosas y metodos. |
MX2020007033A (es) * | 2018-01-05 | 2021-02-26 | Immunext Inc | Anticuerpos anti-mct1 y usos de estos. |
CN112584837A (zh) | 2018-08-31 | 2021-03-30 | 细胞内治疗公司 | 新方法 |
CA3108558A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
US11407828B2 (en) | 2019-02-01 | 2022-08-09 | Novarock Biotherapeutics, Ltd. | Anti-CLauDiN 18 antibodies and methods of use thereof |
WO2020243616A1 (en) * | 2019-05-31 | 2020-12-03 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | E-cadherin activating antibodies and uses thereof |
CN112876564B (zh) * | 2019-11-29 | 2022-07-15 | 康诺亚生物医药科技(成都)有限公司 | 一种tslp相关病症治疗剂的开发和应用 |
CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
WO2023028612A2 (en) | 2021-08-27 | 2023-03-02 | Board Of Regents, The University Of Texas System | Anti-tslpr (crlf2) antibodies |
WO2023155132A1 (zh) * | 2022-02-18 | 2023-08-24 | 绍兴守仁医疗健康科技有限公司 | Rac1蛋白单克隆抗体及其制备方法与应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2077279E (pt) * | 2000-06-28 | 2012-09-14 | Amgen Inc | Moléculas do receptor de linfopoietina estromal tímica e suas utilizações |
CA2577631A1 (en) * | 2004-08-20 | 2006-03-02 | Amgen Inc. | Methods and compositions for treating allergic inflammation |
AU2007230868B2 (en) | 2006-01-13 | 2012-02-02 | Irm Llc | Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases |
KR20100034015A (ko) * | 2007-06-20 | 2010-03-31 | 아이알엠 엘엘씨 | 알레르기 질환 치료를 위한 방법 및 조성물 |
-
2009
- 2009-02-06 CA CA2713935A patent/CA2713935C/en active Active
- 2009-02-06 US US12/863,839 patent/US8475793B2/en active Active
- 2009-02-06 EP EP09709406.4A patent/EP2250199B1/en active Active
- 2009-02-06 CN CN2009801110754A patent/CN101986784A/zh active Pending
- 2009-02-06 MX MX2010008688A patent/MX2010008688A/es active IP Right Grant
- 2009-02-06 WO PCT/US2009/033383 patent/WO2009100324A1/en active Application Filing
- 2009-02-06 AR ARP090100415A patent/AR070346A1/es not_active Application Discontinuation
- 2009-02-06 JP JP2010546045A patent/JP2011511638A/ja active Pending
-
2013
- 2013-07-31 JP JP2013158570A patent/JP2013223516A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2009100324A1 (en) | 2009-08-13 |
CN101986784A (zh) | 2011-03-16 |
CA2713935C (en) | 2016-11-01 |
CA2713935A1 (en) | 2009-08-13 |
JP2013223516A (ja) | 2013-10-31 |
JP2011511638A (ja) | 2011-04-14 |
US20110020369A1 (en) | 2011-01-27 |
MX2010008688A (es) | 2010-08-30 |
EP2250199B1 (en) | 2015-09-02 |
EP2250199A1 (en) | 2010-11-17 |
US8475793B2 (en) | 2013-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR070346A1 (es) | Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos | |
AR096895A2 (es) | Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp) | |
CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
CR20130351A (es) | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina (diviisional 9819) | |
EA201070596A1 (ru) | Гуманизированные антитела против tl1a | |
AR065496A1 (es) | Anticuerpos anti- il-23 r | |
CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
CO6251325A2 (es) | Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr) | |
PE20110668A1 (es) | Anticuerpos anti-linfopoyetina estromal timica (anti-tslp) | |
AR052959A1 (es) | Anticuerpos anti- ccr5 y usos de los mismos | |
EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
EA201170030A1 (ru) | Il-6-опосредованная иммунотерапия | |
PE20080846A1 (es) | Composiciones y metodos relacionados con los anticuerpos receptores de glucagon | |
EA200802168A1 (ru) | Гуманизированное антитело к с-kit | |
EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
EA201070585A1 (ru) | Композиции, содержащие антитела к vegf, и способы | |
ECSP099656A (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
CL2013000843A1 (es) | Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso. | |
AR058955A1 (es) | Inmunglobulinas que se unen a interleuquina 13 | |
ATE469658T1 (de) | Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung | |
AR079336A1 (es) | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) | |
AR082163A1 (es) | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos | |
EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |